Drugs /

toremifene

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
toremifene
Trade Name(s):
Fareston
NCI Definition [1]:
A nonsteroidal triphenylethylene antiestrogen. Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM). This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity. Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. (NCI04)

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for toremifene

Toremifene has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating toremifene, 1 is phase 2 (1 open) and 1 is phase 3 (1 open).

ER Positive, CYP2D6*10, and CYP2D6*14 are the most frequent biomarker inclusion criteria for toremifene clinical trials.

Breast carcinoma is the most common disease being investigated in toremifene clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Toremifene
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating toremifene and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Fareston, 89778-26-7, ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethyl-, (z)-, (z)-2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-n,n-dimethylethanamine, toremifene [chemical/ingredient], tor, toremifene (product), (z)-4-chloro-1,2-diphenyl-1[4-[2-(n,n-dimethylamino)ethoxy]phenyl]-1-butene, toremifene, toremifene, farestone, toremifenum, toremifeno, toremifene (substance)
Drug Categories [2]:
Selective androgen receptor modulators (SARMs)
NCIT ID [1]:
C1256
SNOMED ID [1]:
C-A3220

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.